Trials / Withdrawn
WithdrawnNCT04441398
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Azidus Brasil · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only.
Detailed description
The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only. After 7 days of treatment, the Investigator can extend the treatment duration for another 7 days at his/her discretion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nitazoxanide | Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion. |
| DRUG | Placebo | Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2020-06-22
- Last updated
- 2022-10-28
Source: ClinicalTrials.gov record NCT04441398. Inclusion in this directory is not an endorsement.